Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

thyroid cancer

- PMLiVE

New hires at Amgen, Eli Lilly and Zosano

The latest movers in pharma

Eli Lilly HQ

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Company still hopes drug can show promise in other cancer types

- PMLiVE

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Company says decision is not related to Brexit

- PMLiVE

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis

AstraZeneca AZ

AstraZeneca sells Losec rights as part of refocus strategy

Funds will be diverted to bolster main therapy areas

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

FDA clears Lilly’s Taltz for ankylosing spondylitis

New indication boosts $1bn+ hopes for this year

- PMLiVE

Lilly psoriasis drug beats J&J’s Tremfya in head-to-head trial

Shifting expectations in psoriasis outcomes

- PMLiVE

GSK hires Merck KGaA exec to lead US pharma business

Martinez-Davis will help strengthen company’s oncology focus

- PMLiVE

Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

Hopes to catch up with rivals in the market

- PMLiVE

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links